An Open-label, Randomized Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 96
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
The purpose of this study is to evaluate the pharmacokinetics and bioequivalence of Ritonavir tablet 100 mg versus NORVIR 100 mg tablet in healthy Chinese adult participants under fasting or fed condition.
详细描述
The study design is an Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence Study with a washout period of 6 days. During each session, the subjects will be administered a single dose of 100mg Ritonavir (one Ritonavir Tablet 100mg or one NORVIR Tablet 100mg) under fasting or fed condition.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult volunteers of 18-45 years old.
- •Male (weight ≥50kg);Female (weight ≥45kg)
- •Body mass index (BMI) between 19~28 kg/m2;
- •In good health as determined by a physician/investigator based on medical history, vital signs, electrocardiogram (ECG), laboratory tests and physical examination findings at screening;
- •Female participant with negative result of HCG test and agrees to use adequate contraception from signing of informed consent form throughout the duration of the study and for 6 months after the last dose of study drug;
- •Male participant agrees to use adequate contraception and have no plan to donate sperm from signing of informed consent form throughout the duration of the study and for 6 months after the last dose of study drug;
- •Subject who totally understand the aim and progress of this clinical trial, make decision by his/her free will, and signed a consent form to follow the progress;
- •In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
排除标准
- •Subject who cannot tolerate venipuncture.
- •Allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator;
- •Subject who has past or present history of any serious diseases, including (but not limited to) digestive, cardiovascular, respiratory, urinary, musculoskeletal, endocrine, psychiatric or neurological, hematologic, immunological or metabolic disorders;
- •Abnormal results of physical examination (hematology, urine test,blood biochemistry etc.), vital signs, laboratory profile, a 12-lead electrocardiogram (ECG) or x-ray with clinical significance.
- •A positive result in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test;
- •Women who is during lactation, pregnancy or plan to have baby recently.
- •Women with positive result of HCG test.
- •Subject who refuse to use adequate contraception from signing of informed consent form throughout the duration of the study and for 6 months after the last dose of study drug;
- •Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as alcohol consumption exceeding 14 units per week) within 6 months preceding this study or is unwilling to agree to abstain from alcohol and drugs throughout the study;
- •Heavy smokers (>5 cigarettes per day) within 6 months preceding this study or is unwilling to agree to abstain from smoking throughout the study;
- •Positive test results for alcohol or drug at Screening;
- •History of hospitalization or surgery within 3 months preceding this study.
- •Blood donation within the last 2 months (>= 400 ml), or have a plan to donate blood within 1 month after this study;
- •Intake of any other drug which might influence the results of the trial during two weeks previous to the start of the study.
- •Participation in another study with an investigational drug within the last 3 months preceding this study;
- •History of gastrointestinal surgery, vagotomy, enterotomy or other surgery that may influence gastrointestinal motility,PH or gastrointestinal absorption.
- •Intake of grapefruit or orange (or other food containing grapefruit or orange) 3 days previous to the start of the study. Intake of tea,coffee or other drink containing coffee more than 1L per day.
- •Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive Ritonavir.
研究组 & 干预措施
fasting group
During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fasting condition.
For group1:
cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg
For group2:
cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg
干预措施: Ritonavir for cycle1 and NORVIR for cycle 2 (Drug)
fasting group
During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fasting condition.
For group1:
cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg
For group2:
cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg
干预措施: NORVIR for cycle 1 and Ritonavir for cycle 2 (Drug)
Fed group
During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fed condition.
For group3:
cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg
For group4:
cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg
干预措施: Ritonavir for cycle1 and NORVIR for cycle 2 (Drug)
Fed group
During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fed condition.
For group3:
cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg
For group4:
cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg
干预措施: NORVIR for cycle 1 and Ritonavir for cycle 2 (Drug)
结局指标
主要结局
Cmax
时间窗: 36 hours post-dose on Day 1,7
Maximum Observed Plasma Concentration for ritonavir Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
Tmax
时间窗: 36 hours post-dose on Day 1,7
Time to Reach the Maximum Plasma Concentration
AUC(0-inf)
时间窗: Time Frame: 36 hours post-dose on Day 1,7
Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for ritonavir
AUC(0-36h)
时间窗: 36 hours post-dose on Day 1,7
Area Under the Plasma Concentration-Time Curve From Time 0 to 36 hours Postdose for ritonavir
次要结局
未报告次要终点